Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Myeloid, Acute 95Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 16Myelodysplastic Syndromes 15Leukemia 13Leukemia, Biphenotypic, Acute 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Multiple Myeloma 6Lymphoma, Follicular 6Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Neoplasm, Residual 4Leukemia, B-Cell 3Chromosome 17 deletion 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Hematologic Neoplasms 2

Interventions

Cyclophosphamide 10ofatumumab 8fludarabine 6Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3obinutuzumab 3ibrutinib 3acalabrutinib 3Melphalan 3pirtobrutinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × venetoclax × Clear all
NCT03766763 2025-11-26

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

French Innovative Leukemia Organisation

Phase 2 Active not recruiting
82 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT04515238 2025-06-10

CLL2-BZAG

German CLL Study Group

Phase 2 Active not recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

German CLL Study Group

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡